- Home
- EDRY vs TENX Comparison
EDRY vs TENX Comparison
Compare EDRY & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- TENX
- Stock Information
- Founded
- EDRY 2018
- TENX 1967
- Country
- EDRY Greece
- TENX United States
- Employees
- EDRY N/A
- TENX N/A
- Industry
- EDRY Marine Transportation
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- EDRY Consumer Discretionary
- TENX Health Care
- Exchange
- EDRY Nasdaq
- TENX Nasdaq
- Market Cap
- EDRY 27.3M
- TENX 27.3M
- IPO Year
- EDRY N/A
- TENX N/A
- Fundamental
- Price
- EDRY $12.20
- TENX $6.30
- Analyst Decision
- EDRY
- TENX Strong Buy
- Analyst Count
- EDRY 0
- TENX 4
- Target Price
- EDRY N/A
- TENX $16.67
- AVG Volume (30 Days)
- EDRY 2.2K
- TENX 34.4K
- Earning Date
- EDRY 08-11-2025
- TENX 11-12-2025
- Dividend Yield
- EDRY N/A
- TENX N/A
- EPS Growth
- EDRY N/A
- TENX N/A
- EPS
- EDRY N/A
- TENX N/A
- Revenue
- EDRY $49,707,775.00
- TENX N/A
- Revenue This Year
- EDRY N/A
- TENX N/A
- Revenue Next Year
- EDRY $28.45
- TENX N/A
- P/E Ratio
- EDRY N/A
- TENX N/A
- Revenue Growth
- EDRY N/A
- TENX N/A
- 52 Week Low
- EDRY $7.60
- TENX $3.25
- 52 Week High
- EDRY $20.79
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- EDRY 67.96
- TENX 68.85
- Support Level
- EDRY $10.70
- TENX $6.02
- Resistance Level
- EDRY $12.48
- TENX $6.25
- Average True Range (ATR)
- EDRY 0.20
- TENX 0.13
- MACD
- EDRY 0.14
- TENX 0.03
- Stochastic Oscillator
- EDRY 84.96
- TENX 100.00
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.